Navigation Links
Cancer Advocacy Organization Confronts the Source of rBGH, Demands Pharmaceutical Giant Eli Lilly Stop 'Milking Cancer'
Date:9/22/2009

Breast Cancer Action Challenges Pharma Giant's Marketing of the Artificial Hormone, Asks the Public to Demand Action

SAN FRANCISCO, Sept. 22 /PRNewswire-USNewswire/ -- Breast Cancer Action (BCA), known as the watchdog of the breast cancer movement, today announced the launch of their "Milking Cancer" campaign challenging the pharmaceutical giant Eli Lilly to stop manufacturing rBGH. rBGH (recombinant bovine growth hormone, also known as rBST) has long been linked to cancer.

Eli Lilly is the sole manufacturer of rBGH which is sold worldwide under the name Posilac. The company also markets drugs to treat breast cancer and a drug to reduce the risk of breast cancer in women at high risk.

"Eli Lilly profits from cancer any way you look at it," said Barbara Brenner executive director of Breast Cancer Action. "It's the perfect profit cycle. When Eli Lilly milks cancer, it's great for the company, but bad for the public's health."

The artificial hormone rBGH has been banned in Japan, Australia, Canada and the European Union. Large corporations such as Wal-Mart and Starbucks no longer use milk from rBGH-treated cows in their store-brand products.

"There is strong evidence of a connection between rBGH and cancer, including breast cancer," according to Dr. Martin Donohoe, Adjunct Associate Professor, School of Community Health, Portland State University. "Many leading dairies and health care facilities have eliminated its use. Why should we take a chance with the public's health?"

BCA is launching the Milking Cancer campaign --featuring an on-line video and website, (www.milkingcancer.org) - to raise awareness and to encourage concerned consumers to contact Eli Lilly directly and tell them to stop manufacturing rBGH.

This
'/>"/>

SOURCE Breast Cancer Action
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Study of adjuvant endocrine treatment for breast cancer reveals cost of noncompliance
2. Switching early breast cancer patients to exemestane improves long-term survival
3. Cancer predisposition from genetic variation shows strong gender bias
4. Head, Neck Cancer Treatment Often Not Completed
5. Researchers Propose Improved Cervical Cancer Screening
6. World Health Organization Launches New Attack on Lung Cancer
7. John Theurer Cancer Center and Leukemia & Lymphoma Society Highlight Upcoming Trends in Hematological Malignancies
8. News from Medialink and P&G: Procter & Gamble Partners with National Breast Cancer Foundation, Inc. to GIVE HOPE to Millions of Women Across the Country
9. Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer
10. Surgeon Battling Own Cancer Developed New Treatment
11. New Chemo Regimen May Benefit Ovarian Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... 21, 2014 The Laboratory Testing Services ... manufacturers perform tests on items ranging from consumer and ... society, pressure on operators to ensure the safety and ... greater number of government safety regulations and consumer lawsuits ... to sale. Although revenue briefly dipped in 2009 as ...
(Date:9/21/2014)... York, NY (PRWEB) September 21, 2014 ... enabled more generic drugs to inundate the market, thereby ... Pharmaceutical Manufacturing industry. According to data from Industry ... has cost the industry $1.8 and $2.5 billion in ... brand-name drugs losing patent exclusivity, which has hampered revenue ...
(Date:9/21/2014)... 22, 2014 The asthma market ... as it has become saturated with relatively efficacious ... corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), ... increasing generic competition. However, the launch of seven ... ICS/LABA therapies delivered by the next-generation inhalers will ...
(Date:9/21/2014)... The Illinois Joining Forces Behavioral Health ... symposium ( tinyurl.com/ILBHC14 ) focused on improving care ... by the VNA Foundation, Thresholds, Illinois Department of ... & Disability Advocates, the symposium will be held ... Springfield, IL. The symposium features keynote speakers ...
(Date:9/21/2014)... September 21, 2014 Hundreds of ... forward in Pennsylvania’s Philadelphia Court of Common Pleas, ... the proceeding’s next monthly meeting has been scheduled ... 100300296) , “Our Firm is representing a number ... this litigation. We are pleased with its continued ...
Breaking Medicine News(10 mins):Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4
... say combining a 6 percent salicylic acid gel with ... for plaque psoriasis, an inflammatory skin condition characterized by ... study 30 adults with plaque-type psoriasis were observed for ... acid gel plus 0.1 percent tacrolimus ointment or 6 ...
... According to findings of a recent study researchers say ... kidney stone formation.//Researchers believe larger body size causes increased ... higher risk for calcium-containing kidney stones. ,The association ... gain, body mass index, and waist circumference was studied ...
... past have shown conflicting results over whether hormone replacement ... A recent study however examines the pros and cons ... used combined HRT therapy for five years. All the ... participants had menopausal symptoms, while others did not.Results showed ...
... intake during pregnancy may increase the likelihood of eczema ... according to a recent study.// ,2,000 women were ... the development of asthma and eczema in children. The ... women. The participants were required to fill out questionnaires ...
... results suggest people who carry a gene that produces ... a small increased risk for stroke.// ,Researchers reviewed ... was found that previous study results were observational in ... out confounding factors by looking at data on the ...
... Year has brought with it a new lease of life ... //patients the uphill struggle doesn’t stop with finding a matching ... Research has shown that despite all high tech matching done ... phenomenon. Transplant surgeon Ignazio Marino, M.D., of Thomas Jefferson University ...
Cached Medicine News:
(Date:9/19/2014)... Sept. 19, 2014 UBM Medica US announces ... online community to help oncologists and other clinicians gain ... the use of targeted therapies and immunotherapies, discusses some ... treatment.  Every September, Blood Cancer ... raise awareness about blood cancers—helping to increase survival rates ...
(Date:9/19/2014)... Sept. 19, 2014  Pressure BioSciences, Inc. (OTCQB: ... has received and approved all parts required to ... has begun to manufacture the new PCT-based instrument ... be ready for shipment by mid-October and that ... at a rate of about one per week ...
(Date:9/19/2014)...  Over 200 runners participated in the fifth annual ... Oncology Institute (ROI), hosted by Radiation Business Solutions. This year ... San Francisco.  "Donations are still coming ... Business Solutions, "but at this point, through registrations ... the ROI this year. This surpasses last year,s record ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3
... Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced ... approval for Pixuvri™ (pixantrone dimaleate) for the treatment ... aggressive non-Hodgkin,s lymphoma ("NHL") was validated and accepted ... Validation indicates that the application is complete and ...
... 2010 Hanger Orthopedic Group, Inc. (NYSE: ... (the "Offer") for any and all of its outstanding 10 ... expired at 8:00 a.m., New York City time, on November 17, ... $172,443,000 aggregate principal amount of Notes had been validly tendered ...
Cached Medicine Technology:The European Medicines Agency Validates and Accepts Cell Therapeutics' Marketing Authorization Application for Pixuvri™ 2The European Medicines Agency Validates and Accepts Cell Therapeutics' Marketing Authorization Application for Pixuvri™ 3Hanger Orthopedic Group, Inc. Announces Expiration of Offer to Purchase Outstanding 10 1/4% Senior Notes Due 2014 2Hanger Orthopedic Group, Inc. Announces Expiration of Offer to Purchase Outstanding 10 1/4% Senior Notes Due 2014 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: